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Phaeochromocytomas are catecholamine-secreting tumours of 
neuroectodermal origin. Approximately 85% arise from chromaffin 
cells in the adrenal medulla, and 15% arise from chromaffin tissue in 
extra-adrenal sites extending from the neck to the pelvis, although most 
are found intra-abdominally. Extra-adrenal phaeochromocytomas 
are also referred to as paragangliomas.
The prevalence of phaeochromocytoma in patients with 
hypertension is estimated to be 0.1 - 0.6%.1 Although these 
tumours are rare, their detection is of the utmost importance – 
they are potentially lethal owing, firstly, to their ability to secrete 
catecholamines, often with catastrophic consequences, and, secondly, 
to their potential to become malignant. The frequency of malignant 
phaeochromocytomas ranges from 3% to 36%.2 Early detection and 
removal offers a real chance of cure.
Although most phaeochromocytomas are sporadic, up to 24% 
of patients with apparently sporadic phaeochromocytoma may 
be carriers of mutations.3 The familial syndromes associated with 
phaeochromocytoma are inherited in an autosomal dominant 
manner and include multiple endocrine neoplasia type 2 (MEN-2), 
von Hippel-Lindau (VHL) syndrome, neurofibromatosis type 1 
(NF-1), and familial paraganglioma. Germline mutations for each of 
these syndromes have been identified and allow screening of high- 
risk individuals.1
The clinical presentation of phaeochromocytoma varies, and the 
diagnosis therefore requires a high index of suspicion. If suspected 
clinically, the presence of phaeochromocytoma should first be 
confirmed biochemically, followed by tumour localisation. Tumour 
removal (if feasible) is performed after stabilisation using an 
α-adrenergic blocker.
Phaeochromocytomas occur in all races, but have been 
predominantly reported in Caucasians.2 Reports of this tumour 
from sub-Saharan countries are rare, consisting of single case studies 
or small series.4,5 In this study, the clinical presentation, tumour 
localisation, and outcome of phaeochromocytoma in black patients 
presenting to a tertiary care centre were determined. It is the largest 
reported from sub-Saharan Africa and is an extension of an earlier 
report.6
Patients and methods
Chris Hani Baragwanath Hospital (CHBH) is a 3 000-bed University 
of the Witwatersrand tertiary referral teaching hospital. It serves 
the historically disadvantaged community of Soweto and beyond, 
numbering several million people, almost all of whom are black.
Hospital records of patients presenting with phaeochromocytoma 
to the Endocrine Unit of CHBH between 1980 and 2009 were 
reviewed. All patients were seen and managed by the author. In 
all cases (except the patient diagnosed at autopsy), the diagnosis 
of phaeochromocytoma was confirmed biochemically prior to 
surgery and confirmed histopathologically. This study was approved 
unconditionally by the Human Research Ethics Committee (Medical) 
of the University of the Witwatersrand – Clearance certificate: 
M090960.
Results
Fifty-four patients with phaeochromocytoma were seen between 
1980 and 2009. Their clinical characteristics are shown in Table I. 
All were black: 51 from South Africa, 2 from Botswana and 1 from 
the Democratic Republic of Congo; 41 were female and 13 male 
(F:M, 3.2:1). Ages ranged between 8 and 57 years, and 8 were under 
16 years old (Fig. 1). All diagnoses of phaeochromocytoma were 
made during life, with one exception, who was diagnosed at autopsy 
following a presentation suggestive of a phaeochromocytoma-induced 
multisystem crisis: shock, disseminated intravascular coagulation, 
renal failure, and metabolic acidosis. An extra-adrenal tumour Corresponding author: K Huddle (kenneth.huddle@wits.ac.za)
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Objective. Phaeochromocytomas are catecholamine-secreting 
tumours, the majority of which arise from the adrenal medulla. 
Untreated, they are potentially lethal; early diagnosis and treatment 
offer a good chance of cure. They are rarely reported in blacks. The 
clinical presentation and outcome of phaeochromocytoma in a 
large cohort of black South Africans is reviewed.
Methods. Patients’ records in a tertiary care university 
hospital were reviewed. Fifty-four black patients presenting with 
phaeochromocytoma between 1980 and 2009 were included. The 
clinical presenting features, tumour localisation and outcome were 
assessed.
Results. Fifty-four (41 female, 13 male; age range 8 - 57 years) 
patients were identified. Five (9%) had familial syndromes; 49 
(91%) were deemed sporadic. All tumours were intra-abdominal: 
34 (61%) were adrenal and 22 (39%) extra-adrenal in origin. 
The most common symptoms were headache (77%), palpitations 
(77%), and sweating (74%). All were hypertensive, almost equally 
divided between paroxysmal and sustained hypertension. Six 
(11%) presented in congestive cardiac failure including 2 with 
catecholamine-induced myocarditis. Two patients had features 
which simulated hypertrophic obstructive cardiomyopathy. Nine 
women presented in pregnancy: there was no maternal mortality; 
fetal mortality included 1 early neonatal death and 1 intrauterine 
death. There were 4 deaths: 1 from postoperative haemorrhage, 
1 from multisystem crisis, 1 from metastatic medullary thyroid 
carcinoma, and 1 from catecholamine-induced myocarditis.
Conclusion. Phaeochromocytoma is an important although 
rare tumour in blacks, with similar clinical presentations and 
complications to those in white patients. Timely diagnosis and 
appropriate treatment resulted in a favourable outcome in over 90% 
of patients in this study.
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was found at autopsy. Forty-nine patients (91%) were classified as 
sporadic, and 5 (9%) were associated with familial syndromes. Nine 
tumours were detected during pregnancy. Malignancy was diagnosed 
in 3 patients.
All tumours were intra-abdominal: 34 (61%) were adrenal in 
origin (2 patients had bilateral adrenal tumours); 22 (39%) were 
extra-adrenal including 2 in the Organ of Zuckerkandl and 1 in the 
urinary bladder. Tumour size was recorded in 49 cases with benign 
tumours and ranged from 3 cm × 3 cm × 3 cm to the largest at 19 
cm × 16 cm × 17 cm (Fig. 2), with an average size of 6.9 cm × 5.6 cm 
× 4.2 cm.
Selected aspects
Cardiovascular complications
Hypertension (blood pressure >140/90 mmHg) was present in 100% 
of patients. In approximately half of them, the hypertension was 
classified as paroxysmal and was sustained in the other half. This 
distinction was not always easy as the blood pressure was often 
labile, even in patients with sustained hypertension. As indices of the 
severity of hypertension, 49% of patients had evidence of grades 3 or 
4 hypertensive retinopathy, 2 patients presented with hypertensive 
encephalopathy, and 82% had clinical, electrocardiographic or 
echocardiographic evidence of left ventricular hypertrophy. Only 
1 patient had established renal failure which was secondary to 
multisystem crisis, although patients often presented with an isolated 
elevation of the serum urea which subsequently normalised on 
α-adrenergic blockade and volume repletion.
Six (11%) patients presented in congestive cardiac failure. An 
8-year-old girl (previously reported)7 presented in cardiogenic shock. 
It took 2 months on medical therapy to stabilise her cardiac function 
to allow the removal of an adrenal phaeochromocytoma, and a 
further 4 months for full recovery of cardiac function. A 16-year-old 
boy developed irreversible pulmonary oedema despite comprehensive 
Table I. Clinical presentation of 54 patients with  
phaeochromocytoma
Clinical features Percentage positive
Hypertension 100
   paroxysmal 53
   sustained 47
Headache 77
Palpitations 77
Sweating 74
Grade 3/4 retinopathy 49
Dizziness 40
Nausea and vomiting 38
Abdominal pain 34
Weight loss 26
Heat intolerance 26
Dyspnoea 23
Hyperglycaemia 19
Visual disturbance 19
Fatigue 17
Constipation 15
Chest pain 13
Cardiac failure 11
Syncope 11
Anxiety 9
Tinnitus 6
Abdominal mass 6
Back/flank pain 6
Encephalopathy 4
HOCM 4
Multisystem crisis 2
HOCM = hypertrophic obstructive cardiomyopathy.
Fig. 1. Age and gender distribution of 54 patients presenting with phaeochro-
mocytoma.
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Fig. 2. CT scan showing a giant cystic left adrenal phaeochromocytoma 
(arrow).
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medical therapy while awaiting surgery. At autopsy, the heart showed 
left ventricular hypertrophy with widespread myocytolysis and an 
inflammatory cell infiltrate – findings in keeping with a catecholamine-
induced cardiomyopathy. In the remaining 4 patients, heart failure 
was attributed to hypertensive heart disease which responded rapidly 
to medical therapy, including α-adrenergic blockade. Two patients 
(previously reported)8 presented with clinical and echocardiographic 
features simulating hypertrophic obstructive cardiomyopathy. Both 
had successful tumour removal that led to regression of the abnormal 
clinical features, normalisation of the electrocardiographs, but only 
partial regression of the echocardiographic features, after follow-up 
for 24 and 32 months respectively.
Pregnancy
Nine patients presented during pregnancy (Table II), the first 4 of 
whom were reported previously.9 Seven women presented in the 
third, 1 in the second, and 1 at the end of the first trimester. All 
patients, with the exception of Case 8, were delivered by caesarean 
section (CS). Tumour resection took place at the time of CS in 5 
patients, and several weeks postpartum in 2 patients. Case 5 had a 
successful tumour removal at 20 weeks’ gestation followed 17 weeks 
later by CS. Case 9 had tumour resection at 23 weeks. There was 
no maternal mortality. In Case 3, signs of fetal distress appeared at 
29 weeks’ gestation that necessitated emergency CS. The premature 
baby had poor Apgar scores and died 3 days later from respiratory 
distress syndrome and intraventricular haemorrhage. Case 9 had 
bilateral adrenal phaeochromocytomas removed at 23 weeks, with 
the intention of continuing medical therapy until fetal maturity was 
attained. However, she experienced an intra-uterine death 3 days 
postoperatively while on medical therapy.
Familial syndromes
Familial syndromes were diagnosed in 5 (9%) patients. Two had 
typical clinical features of NF-1. One patient (previously reported)10 
was diagnosed with MEN-2A based on the presence of metastatic 
medullary carcinoma of the thyroid associated with an adrenal 
phaeochromocytoma. A missense mutation in codon 634 of exon 
11 of the RET gene was found. Her phaeochromocytoma was 
successfully removed but she refused further treatment for her 
thyroid malignancy which had spread to the liver. She died 8 years 
later. Three family members were shown to be carrying the mutant 
RET gene, although they showed no clinical abnormalities. They 
declined further investigation.
Two patients had VHL syndrome (submitted for publication). In 
the first, the diagnosis was based on the presence of a symptomatic 
cerebellar haemangioblastoma (Fig. 3) in association with a mildly 
symptomatic adrenal phaeochromocytoma. Genetic testing revealed 
a missense mutation (c.256C>T) in the VHL gene on chromosome 
3p. He underwent successful removal of the phaeochromocytoma 
followed by removal of the cerebellar haemangioblastoma. It 
subsequently became apparent that his father had had a brain tumour 
removed many years previously. Further investigation revealed 
Table II. Data on patients with phaeochromocytoma presenting in pregnancy
Case No. Age (years) GAP (weeks)
Time of tumour 
resection
Mode/time of 
delivery (weeks) Birth weight (g)
Fetal/neonatal 
outcome
1 26 32 Postpartum CS/39 2 730 Alive and well
2 32 26 At CS CS/35 3 110 Alive and well
3 31 25 Postpartum CS/29 1 050 ENND
4 27 31 At CS CS/35 2 680 Alive and well
5 32 12 At 20 weeks CS/37 2 500 Alive and well
6 20 33 At CS CS/35 2 900 Alive and well
7 24 24 At CS CS/27 805 Alive and well
8 38 27 At CS CS/34 1 800 Alive and well
9 29 20 At 23 weeks - - IUD 3 days post-
op
GAP = gestational age at presentation; CS = caesarean section; ENND = early neonatal death; IUD = intrauterine death.
Fig. 3. MRI scan showing a cerebellar haemangioblastoma (solid arrow) 
within a large cyst (broken arrow).
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bilateral renal cell carcinoma for which he received treatment. 
The father and his daughter screened positive for the VHL gene. 
Although the daughter is clinically well, she has evidence on MRI 
of haemangioblastomas in her brain and spinal cord. All 3 affected 
members of this family are being regularly monitored for the 
development of complications associated with the VHL syndrome. 
The second diagnosis of VHL syndrome was made in the pregnant 
woman (Case 9) who had bilateral adrenal phaeochromocytomas. 
There were no clinical features of VHL syndrome; however, MRI 
showed a haemangioblastoma in the cervical spine. Genetic testing 
revealed a missense mutation (c.499C>T) in the VHL gene, located 
on chromosome 3p26-p25. Her 6-year-old daughter screened positive 
for the mutation; her 8-year-old son was negative. Both mother and 
daughter will be investigated further and monitored long-term.
Malignancy
Two children had evidence of malignant disease. The 8-year-old 
girl who had originally presented in cardiogenic shock owing to a 
catecholamine-induced cardiomyopathy (see above), presented 5 
years later with a second adrenal phaeochromocytoma with metastatic 
spread surrounding the superior mesenteric artery. The adrenal 
tumour was removed but the metastasis was deemed unresectable. 
She received a therapeutic dose of 131I-metaiodobenzylguanidine 
(MIBG) but has biochemical and radiological evidence of residual 
tumour. Her blood pressure is controlled with an α-adrenergic 
blocker combined with a calcium channel blocker. She is relatively 
well and attends school, 10 years after the initial presentation.
An 11-year-old boy was diagnosed with a massive abdominal 
phaeochromocytoma which was only amenable to debulking. 
MIBG scan revealed local spread and a metastasis to the skull. He 
subsequently received 2 therapeutic doses of MIBG. He is relatively 
well 8 years after presentation, requiring α- and β-adrenergic blockers 
plus a calcium channel blocker to control his blood pressure.
An adult of 44 years had invasion of an abdominal lymph node by 
tumour following resection of an extra-adrenal phaeochromocytoma. 
The postoperative urinary metanephrines and MIBG scan were 
normal. Close follow-up has been implemented.
Vesical phaeochromocytoma
A 21-year-old man with a history of hypertension complained 
of repeated episodes of dizziness, palpitations and headache 
immediately following micturition.11 This was associated with a 
feeling of impending doom. A phaeochromocytoma was detected in 
the bladder wall and successfully resected.
Outcomes
A summary of mortality data associated with phaeochromocytoma 
in this study is shown in Table III. The 2 fetal/neonatal losses are 
shown in Table II.
Discussion
This study indicates that phaeochromocytoma is an important 
although rare tumour in black patients, with similar clinical 
presentations and complications to those in other reports.2,12,13 
The paucity of reports from sub-Saharan Africa most likely reflects 
limited health care resources in these countries in general, and 
limited laboratory and radiological facilities for diagnosis of 
phaeochromocytoma in particular. Clearly, because of its rarity, 
it is not cost-effective to screen all hypertensive patients for this 
tumour. Rather, one should investigate those patients in whom there 
is a high index of suspicion based on clinical presentation:14 patients 
with episodic symptoms of headache, palpitations and sweating; 
unexplained paroxysms of arrhythmias and/or hypertension 
during intubation, induction of anaesthesia, tumour manipulation, 
and parturition; adverse cardiovascular responses to ingestion, 
inhalation, or injection of certain drugs; spells or attacks occurring 
during exertion, twisting and turning of the torso, straining, coitus 
or micturition; family history of phaeochromocytoma or familial 
syndrome; and incidental adrenal/abdominal masses. Approximately 
90% of patients with phaeochromocytoma are hypertensive, with 
similar proportions of patients with paroxysmal and sustained 
hypertension.2,13,14 Postural hypotension may occur in up to 12% of 
patients. In the present study, headache (77%), palpitations (77%) 
and sweating (74%) were the most common symptoms. This triad 
of symptoms presenting together in a hypertensive patient has been 
reported as having a sensitivity of 90.9% and a specificity of 93.8%.14 
All the patients in this report were hypertensive, almost equally 
divided between paroxysmal and sustained hypertension. Dizziness 
(40%) was also a common symptom; 6 (11%) patients had syncopal 
episodes which, on the basis of circumstantial evidence, were 
attributed to postural hypotension.
A cause for concern is that the diagnosis of phaeochromocytoma 
is often missed. For example, in a series from the Mayo Clinic, 41 
of 54 autopsy-proven cases were unsuspected clinically during life.15 
The many reasons for non-diagnosis include the nonspecific nature 
of the symptoms, the clinicians’ low index of suspicion, and that 
some tumours are asymptomatic because they are non-functioning or 
secrete relatively small amounts of catecholamines.13 Our hospital has 
no reliable autopsy data to assess the situation, but it is highly probable 
that phaeochromocytomas are missed. The patient presenting with 
multisystem crisis was only diagnosed at autopsy.
Cardiac complications of phaeochromocytoma are many and 
varied, including left ventricular hypertrophy (usually concentric), 
catecholamine-induced myocarditis and dilated cardiomyopathy, 
takotsubo cardiomyopathy, and a condition simulating hypertrophic 
obstructive cardiomyopathy (HOCM).2 Catecholamine-induced 
myocarditis may result in cardiac failure and death, often without 
manifesting hypertension.16 Of the 6 patients in this study who 
presented in heart failure, 2 were assessed as having catecholamine-
induced myocarditis; one showed full recovery of cardiac function 
several months after tumour removal; the other had a fatal outcome 
prior to tumour resection. Unexplained cardiac failure/pulmonary 
oedema should make one consider phaeochromocytoma in the 
differential diagnosis. Left ventricular hypertrophy associated with 
phaeochromocytoma may rarely be asymmetrical and mimic the 
features of HOCM, as was the case in 2 of our patients, showing 
reversibility several years after tumour removal.
Table III. Summary of mortality data associated with  
phaeochromocytoma
Age (years) Sex Cause of death
29 F Multisystem crisis
33 F Postoperative haemorrhage following 
tumour removal
29 F Metastatic medullary thyroid carcinoma 
associated with MEN-2A
13 M Cardiac failure caused by a catecholamine-
induced myocarditis
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Phaeochromocytoma in pregnancy may have devastating 
consequences for both mother and fetus. If undiagnosed during 
pregnancy, phaeochromocytoma is associated with a maternal 
and fetal mortality of around 50%.17 When the diagnosis of 
phaeochromocytoma is made antepartum and when appropriate 
treatment is instituted, maternal mortality has fallen to as low as 
2%, and fetal mortality to 11%.18 The main differential diagnosis in 
pregnancy is pre-eclampsia, which is far more common. Pre-eclampsia 
occurs in the second half of pregnancy and is not associated with the 
typical symptoms associated with phaeochromocytoma. Pregnant 
women with severe/paroxysmal hypertension, symptoms suggestive 
of phaeochromocytoma, abnormal glucose tolerance, and sudden 
collapse should be investigated for phaeochromocytoma. In this 
study there was no maternal mortality. There was 1 early neonatal 
death at 29 weeks and 1 intra-uterine death at 23 weeks’ gestation. 
Gratifyingly, the remaining 7 babies made good progress.
Significant advances have been made in determining the genetic 
basis of phaeochromocytomas; they are associated with the following 
familial syndromes: MEN-2 (activating germline mutations in the 
RET proto-oncogene), VHL syndrome (germline mutations in 
the VHL tumour suppressor gene), NF-1 (germline mutations 
in the NF-1 tumour suppressor gene), and phaeochromocytoma/
paraganglioma syndromes (germline mutations in the B and D 
subunits of mitochondrial succinate dehydrogenase – SDHB and 
SDHD). Genetic testing should be considered in the following 
situations: a positive family history, clinical features of syndromic 
disorder (e.g. MEN-2, VHL), children and young adults with 
phaeochromocytoma, bilateral adrenal tumours or multifocal 
extra-adrenal disease, and paragangliomas. The clinical picture 
and biochemical phenotype can direct the specific genetic testing 
required.1 There are significant benefits associated with genetic 
testing including the early diagnosis of other tumours in a patient 
with a syndromic disorder (e.g. renal cell carcinoma in VHL), 
allowing earlier treatment and improved prognosis; affected family 
members would likewise benefit. In addition, close follow-up of 
patients with germline mutations is indicated to detect additional 
chromaffin tumours or recurrences. Our 5 patients identified with 
familial syndromes are probably an underestimate of the number of 
patients with genetic disorders, as selective genetic testing has only 
recently become available to us.
Conclusion
Phaeochromocytomas will continue to fascinate, confound and 
humble. Their detection via good sleuth work is intellectually very 
satisfying and, in most cases, results in their cure. This report 
highlights the fact that phaeochromocytoma is an important although 
rare tumour in blacks, has a similar profile to that found in whites, 
and that with timely intervention a good outcome can be achieved in 
most patients. Future advances in the understanding of this tumour 
will lead to improved detection, more effective treatment – especially 
for malignant disease – and better outcomes.
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